Progyny, Inc. (PGNY) fair value analysis
Nasdaq · Updated 2026-10-19
PGNY price how computed
Forward Fair Value verdict
UndervaluedPGNY is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $26.86
- Sector
- Healthcare
- 12-month range
- $16.30–$32.36
- Market cap
- $2.06B
- From 52-week high
- -17.0%
- Shares outstanding
- 76.7M
- Rank in Healthcare by discount to fair value
- #16 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Progyny, Inc. is a healthcare company that provides fertility and family-building benefits solutions, offering services such as fertility treatments, adoption assistance, and surrogacy support to employers and their employees. The company operates in the United States, serving as a benefits administrator and care coordinator for its clients.
PGNY currently ranks #16 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $2.06B
- P/E (trailing)
- 19x
- Revenue (TTM)
- $1.31B
- Net margin
- 6.0%
- EPS (TTM)
- $1.43
- Gross margin
- 25.5%
- Debt / equity
- 0.06
- Revenue growth (3-yr avg)
- 8.3%
- Shares outstanding
- 76.7M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 46 · neutral
- 50-day average
- $26.45
- 200-day average
- $24.27
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+21.4%)
2026-03 ▲ beat (+13.6%)
2025-12 ▲ beat (+7.7%)
2025-09 ▲ beat (+15.4%)
2025-06 ▲ beat (+11.8%)
2025-03 ▲ beat (+6.7%)
2024-12 ▲ beat (+13.5%)
2024-09 ▲ beat (+8.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 2 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $34.4
- Target vs last price
- +28.1%
What our data shows for PGNY
- Our model validated 16 trailing price-to-earnings windows for PGNY, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $16.30–$32.36.
- The 14-day relative strength index sits at a neutral 46.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PGNY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PGNY news
TickrTrends' derived news-sentiment signal for PGNY is currently leaning positive, computed from recent coverage.
- Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report (manilatimes.net, 2026-10-21)
TickrTrends take: Progyny, Inc. is scheduled to report its third quarter 2026 results, providing an opportunity for investors to assess the company's operational performance against its current undervalued designation according to TickrTrends analysis. A valuation-focused reader should monitor revenue trends, profitability metrics, and any updates to the company's market position within the Healthcare sector to determine whether the undervalued assessment remains justified. The earnings report will offer concrete financial data that can either support or challenge the current valuation verdict. - Progyny Inc (PGNY) Stock Up 3.6% and Still Undervalued -- GF Score: 94/100 (gurufocus.com, 2026-10-20)
TickrTrends take: Progyny's recent stock movement and exceptional GF Score of 94 out of 100 align with TickrTrends' undervalued assessment, suggesting the market has not fully priced in the company's fundamental strength. For valuation-focused readers, the combination of strong quality metrics and below-intrinsic-value pricing indicates potential margin of safety in a Healthcare sector company that continues to demonstrate operational excellence. Monitoring whether institutional investors recognize this valuation gap could provide insight into whether the current undervaluation represents a temporary market inefficiency or reflects underlying sector headwinds. - PGNY Initiates Coverage On Wells Fargo -- Rating Set to Overweight (gurufocus.com, 2026-09-30)
TickrTrends take: Wells Fargo has initiated coverage of Perineal Health Inc with an Overweight rating, which aligns with TickrTrends' current assessment that the stock is Undervalued in the Healthcare sector. When established financial institutions begin coverage with positive ratings, it can signal growing analyst attention and potential institutional interest in a company, factors that valuation-focused investors typically monitor as indicators of market recognition. Observers should track whether this new coverage influences trading volume and whether analyst estimates shift in response to Wells Fargo's positioning on the company.
More PGNY news
- Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 (NASDAQ:PGNY) (seekingalpha.com, 2026-09-17)
- Progyny: Slow But Consistent Growth With A Pristine Balance Sheet (NASDAQ:PGNY) (seekingalpha.com, 2026-09-05)
What people are saying
Follow the PGNY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — # PGNY Weekly Summary TickrTrends' derived indicators for PGNY show a shift in the 50/200-day trend state from mixed to uptrend this week. The current valuation verdict remains undervalued. These changes suggest an improving technical position for the healthcare sector stock.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PGNY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), PGNY is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is PGNY's TickrTrends verdict?
PGNY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does PGNY compare to other Healthcare stocks?
PGNY ranks #16 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is PGNY overbought or oversold?
PGNY's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PGNY report earnings next?
PGNY's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does PGNY usually beat earnings estimates?
Over its last 8 reported quarters PGNY beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PGNY?
Of 12 analysts covering PGNY, 10 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $34.4 (+28.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
PGNY vs DXCM · PGNY vs IDXX · PGNY vs INDV · PGNY vs ISRG · PGNY vs LMAT